Orion-konsernin tilinpäätöstiedote tammi–joulukuu 2025

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• 2026 revenue expected to be 1,900-2,100 million EUR

  80% confidence

• Nubeqa has repeatedly exceeded expectations

  80% confidence

• Orion's performance was very strong in 2025 with solid financial results and clear progress in strategy implementation

  80% confidence

• Generics and Consumer Health sales expected to be at same level or slightly higher than 2025

  80% confidence

• No material change expected in total investment volume in 2026 compared to 2025

  80% confidence

• Sales and marketing expenses expected to increase in 2026

  80% confidence

• Orion's booked annual Nubeqa sales have potential to exceed 1 billion EUR by end of current decade

  80% confidence

• Animal Health business unit expected to grow slightly in 2026

  80% confidence

• Q4 2025 was a strong quarter that was a great ending to successful year 2025

  80% confidence

• ODM-212 and its mechanism of action have significant potential in different indications

  80% confidence

• Expects another very strong year in 2026 with continued work building wellbeing and Orion's future

  80% confidence

• Company aims to expand ODM-212 phase 2 program during 2026

  80% confidence

• Orion's booked Nubeqa royalties and product sales expected to grow significantly in 2026

  80% confidence

• Branded Products business unit expected to grow in 2026 with respiratory diseases therapy area and Easyhaler portfolio as growth drivers

  80% confidence

• 2026 operating profit expected to be 550-750 million EUR

  80% confidence

• R&D expenses expected to increase in 2026 compared to 2025

  80% confidence

Cited in these Via News reports

• Gene Therapy, mRNA and CRISPR: The Global Biotech Boom Reshaping How the World Finances Medicine →
• Global Pharma Giants Redraw Strategic Maps as M&A Wave and Pipeline Milestones Reshape the Sector →